Trending at Lumira Ventures

Fusion Pharmaceuticals Announces Preliminary Safety And Dosimetry Results From Its Single-Dose Portion Of The Phase 1 Study Of FPI-1434

Altamash Hashmi Fusion Pharmaceuticals, Portfolio News

Product candidate FPI-1434, administered at three different dose levels, demonstrated a favorable safety profile with no drug-related serious adverse events or dose-limiting toxicity Imaging shows drug uptake across multiple tumor types Enrollment in multi-dosing cohorts continues Fusion also reported preclinical …

Fusion Pharmaceuticals Appoints Isabelle Dussault, Ph.D. As Senior Vice President, Research

Altamash Hashmi Fusion Pharmaceuticals, Portfolio News

HAMILTON, ON and BOSTON, June 7, 2021: Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Isabelle Dussault, Ph.D. as senior vice president, research. “Isabelle brings deep oncology research experience, including …

Fusion Pharmaceuticals, A Lumira Portfolio Company, Enters Into Agreement To Build Radiopharmaceutical Manufacturing Facility

Altamash Hashmi Fusion Pharmaceuticals, Portfolio News

HAMILTON, ON and BOSTON, June 2, 2021: Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it entered a 15-year lease agreement with Hamilton, Ontario-based McMaster University to build a 27,000 square foot current Good Manufacturing …

Fusion Pharmaceuticals, Lumira Portfolio Company, Announces Clinical Collaboration with Merck to Evaluate Fusion’s Targeted Alpha Therapy (TAT) in Combination with Merck’s KEYTRUDA® (Pembrolizumab) in Patients With Solid Tumors Expressing IGF-1R

Altamash Hashmi Fusion Pharmaceuticals, Portfolio News

HAMILTON, ON and BOSTON, May 6, 2021 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has entered into a clinical trial collaboration with a subsidiary of Merck (known as …

Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen

Abi Kumar Fusion Pharmaceuticals, Portfolio News

Fusion to Leverage its Targeted Alpha Therapies (TAT) Expertise to Create FPI-2059, an Alpha-Emitting Radiopharmaceutical Targeting Solid Tumors HAMILTON, ON and BOSTON, March 2, 2021 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as …